Department of Radiotherapy, Klinikum Rechts der Isar, Technical University, Munich, Germany.
Faculty of Medicine, Technical University, Munich, Germany.
Radiat Oncol. 2018 Nov 7;13(1):218. doi: 10.1186/s13014-018-1160-5.
This study was performed to evaluate skin toxicity during modern three-dimensional conformal radiotherapy (3D-CRT) and to evaluate the importance of dose distribution and patient related factors.
This study comprises 255 patients with breast cancer treated with tangential three-dimensional conformal radiotherapy (3D-CRT) after breast conserving surgery between 03/2012 and 05/2017. The median prescribed dose was 50.4 Gy (range 50-50.4) and 92.2% of the patients received a sequential boost of 10-16 Gy. Adverse skin toxicities (according to CTCAE v. 4.03 and the occurrence of moist desquamations) were assessed at the end of treatment. The dose distribution in the skin (5 mm strip from the patient outline) and in the CTV was evaluated and correlated to the CTCAE scores and the occurrence of moist desquamation.
42.4% of the patients developed grade I, 55.7% grade II and 2% grade III skin toxicities. Moist desquamation was observed in 59 cases (23.1%). Dose distribution within the CTV and skin was homogenous with only small areas receiving 107% of the prescribed dose (median: 0.7 cm) in the CTV and 105% (median 0.5 cm) in the skin. On univariate analysis breast size as well as V107%(CTV), V105%(skin) and V80%(skin) correlated significantly (p < 0.05) with the incidence of skin toxicity. On multivariate analysis only V80%(skin) was confirmed as independent risk factor.
Modern tangential multi-field 3D-CRT allows a homogeneous dose distribution with similar skin toxicity as compared to studies performing IMRT. Dose distribution within the skin (V80%) might have a relevant impact on the severity of skin toxicity and the occurrence of moist desquamation.
本研究旨在评估现代三维适形放疗(3D-CRT)期间的皮肤毒性,并评估剂量分布和患者相关因素的重要性。
本研究纳入了 255 例接受保乳手术后接受切线三维适形放疗(3D-CRT)的乳腺癌患者,入组时间为 2012 年 3 月至 2017 年 5 月。中位处方剂量为 50.4Gy(范围为 50-50.4Gy),92.2%的患者接受了 10-16Gy 的序贯增敏。治疗结束时评估了皮肤不良反应(根据 CTCAE v.4.03 和湿性脱皮的发生情况)。评估了皮肤(距患者轮廓 5mm 带)和 CTV 中的剂量分布,并将其与 CTCAE 评分和湿性脱皮的发生相关联。
42.4%的患者出现了 I 级皮肤毒性,55.7%的患者出现了 II 级皮肤毒性,2%的患者出现了 III 级皮肤毒性。59 例(23.1%)患者出现了湿性脱皮。CTV 和皮肤内的剂量分布均匀,仅有小面积(CTV 中中位数为 0.7cm)和皮肤(中位数为 0.5cm)接受了 107%的处方剂量。单因素分析显示,乳房大小以及 V107%(CTV)、V105%(皮肤)和 V80%(皮肤)与皮肤毒性的发生显著相关(p<0.05)。多因素分析仅证实 V80%(皮肤)是独立的危险因素。
现代切线多野 3D-CRT 可实现均匀的剂量分布,皮肤毒性与行调强放疗的研究相似。皮肤内的剂量分布(V80%)可能对皮肤毒性的严重程度和湿性脱皮的发生有重要影响。